PA4HD
Asset Logo

Panorama Auto Trust 2024-3

πŸ‡¦πŸ‡Ί ASX

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

0
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Class D Frn Mat 15-Sep-2032 Min Cons $5Ht Nc

πŸ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in PA4HD

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in PA4HD

N/A
PA4HD investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in PA4HD also invest in...

Want more shares? Try these...

Patrys Limited

PAB

Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. The company has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.

πŸ™Œ Performance (5Yr p.a)

-16.83%

πŸ“Š Share price

$0.00 AUD

🧬 BIOTECHNOLOGY

Find Out More

Pacific Current Group Ltd. engages in the business of investing in asset managers, private advisory, placement, and investment related firms. The company is headquartered in Sydney, New South Wales and currently employs 20 full-time employees. The firm is engaged in investing in asset managers, private advisory, placement and investment-related firms on a global basis. The firm operates a portfolio of 15 specialist boutiques in Australia, India, Luxembourg, the United States, and the United Kingdom. The Company’s portfolio represents an array of strategies, diversified across investment strategy, geography, revenue model, and client type. Its portfolio of companies includes Aether Investment Partners, LLC, Astarte Capital Partners, LLP, Carlisle Management Company, S.C.A., Cordillera Investment Partners, LP, Victory Park Capital Advisors, LLC and others. Aether Investment Partners, LLC is focused on private investments in natural resources, infrastructure and opportunistic real assets. Astarte Capital Partners, LLP is focused on infrastructure, natural resources, transportation, and real estate.

πŸ™Œ Performance (5Yr p.a)

9.45%

πŸ“Š Share price

$10.75 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ’Έ FINANCIALS

πŸ’° HIGH DIVIDEND

Compare
Add to watchlist